An Extraordinary General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Monday, 22 September 2025 at Bränningevägen 12, 120 54 Årsta. The main…
“A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs…
On Tuesday July 22 at 9:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q2 2025 report (which will have been published earlier on July 22 at 07:30 a.m.…
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed…
Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of Devyser HLA Loss, a next-generation sequencing (NGS) assay designed exclusively to empower…
The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Tuesday, 14 May 2025 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed…
“A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to…
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant new tender in Udine, Italy, valued at SEK 61.8 million over a 36-month period.…
On Tuesday April 29 at 11:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q1 2025 report (which will have been published earlier on April 29 at 10:00 a.m.…
Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science…
